Logo
ホームページ
当社のモデルを探求してください。
カート
連絡先
購読する
モデル製品
HUGOシリーズ 🌟
HUGO-GT™(ヒト化ゲノムオルソログ)
HUGO-Ab™(抗体開発)
HUGO-Mab™ – 完全ヒトモノクローナル抗体マウス
MouseAtlas モデルライブラリ
期間限定セール
研究用動物モデル
Creマウス系統
ヒト化ターゲット遺伝子モデル
代謝疾患モデル
眼科疾患モデル
神経疾患モデル
自己免疫疾患モデル
免疫不全マウスモデル
ヒト化免疫系マウスモデル
腫瘍学・免疫腫瘍学モデル
新型コロナウイルス感染症(Covid-19)用マウスモデル
細胞株モデル
ノックアウト細胞株製品カタログ
iPS細胞株製品カタログ
腫瘍細胞株製品カタログ
AAV 标準製品カタログ
サービス
前臨床薬効評価
神経科学
アルツハイマー病前臨床CROサービス
パーキンソン病前臨床CROサービス
ハンチントン病前臨床CROサービス
血液脳関門(BBB)研究ソリューション
眼科分野
緑内障前臨床CROサービス
加齢黄斑変性(AMD)前臨床CROサービス
がん研究
PBMCヒト化マウスモデル
ヒト免疫システム(HIS)マウスモデル
代謝・循環器系疾患
抗肥満薬開発向け前臨床CROサービス
自己免疫・炎症疾患
喘息前臨床CROサービス
遺伝子改変動物
ノックアウトマウス
トランスジェニックマウス
ノックインマウス
ノックアウトラット
ノックインラット
トランスジェニックラット
遺伝子改変モデルの作製技術
TurboknockoutTMゲノム標的化技術
ターゲティング遺伝子編集
通常型トランスジェニック
PiggyBacトランスジェネシス
BACトランスジェニック
ES細胞ターゲティング
繁殖・サポートサービス
繫殖サービス
凍結保存および回復
表型解析サービス
BAC改変
ウイルスパッケージング
アデノ関連ウイルス(AAV)パッケージング
レントウイルスパッケージング
アデノウイルスパッケージング
カスタム細胞株作製サービス
誘導多能性幹細胞(iPS細胞)
ノックアウト細胞株
ノックイン細胞株
点変異細胞株
過剰発現細胞株
モダリティ
遺伝子治療
AI駆動型AAV開発
核酸医薬
細胞免疫療法
コミュ二ティー
キャンペーン
イベント・ウェビナー
ニュース
研究情報
資料室
データベース
査読済み文献(引用)
希少疾患データセンター
AbSeek
Cell iGeneEditor™ システム
OriCell 細胞培養関連
会社案内
企業概要
施設概要
動物の健康・福祉
健康報告書
協力企業・代理店
採用情報
お問い合わせ
Login
フィルター
フィルター
KO/cKO マウスモデル
フラッシュセール
HUGO-GT™ プラットフォーム
ヒト化ターゲット遺伝子モデル
ヒト化ターゲット遺伝子モデル
免疫ターゲットヒト化モデル腫瘍ターゲットヒト化モデル代謝ターゲットヒト化モデルサイトカインヒト化モデルその他のターゲットヒト化モデル
免疫系マウスモデル
免疫不全マウスモデルヒト化免疫系モデル
遺伝学ツールマウスモデル
Creドライバー系統レポーターマウス系統その他の遺伝学ツール系統
専門疾患モデル
眼科疾患モデル神経疾患モデル代謝疾患モデル腫瘍学・免疫腫瘍学モデル自己免疫疾患モデル希少疾患モデル感染症疾患モデルその他の疾患モデル
2 件の結果が “3558” で取得されました
フィルター
並べ替える:
アルファベット順(A-Z)
ベストセラー
B6-hIL2
製品ID :
C001804
系統:
C57BL/6NCya
状況:
Live Mouse
説明:
The IL2 gene encodes Interleukin-2, a crucial cytokine primarily secreted by activated CD4+ and CD8+ T lymphocytes, and to a lesser extent, by natural killer (NK) cells. This protein, also known as T-cell growth factor, plays a pivotal role in regulating immune responses by promoting the growth, proliferation, and differentiation of various "disease-fighting blood cells", including T cells, B cells, NK cells, monocytes, macrophages, and oligodendrocytes [1]. IL2 expression is tightly regulated; it is upregulated upon T-cell activation through T-cell receptor signaling and can be inhibited by factors like TOB and TGF-beta [2]. The encoded IL-2 protein mediates its effects by binding to the IL-2 receptor (IL-2R), a complex found on lymphocytes, which then activates downstream signaling pathways such as JAK-STAT, PI3K/Akt/mTOR, and MAPK/ERK, influencing T-cell survival, differentiation, and the maintenance of immune tolerance by supporting regulatory T cells (Tregs) while inhibiting pro-inflammatory Th17 cell differentiation [3]. Deregulation of IL2 function, whether due to deficiency or excess, is implicated in various autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, Sjögren's syndrome, and multiple sclerosis, as well as certain cancers like metastatic melanoma, renal cell carcinoma, and non-Hodgkin lymphoma [4]. The B6-hIL2 mouse is a humanized model, constructed by replacing the coding sequences of the endogenous mouse Il2 gene with the coding sequences of the human IL2 gene. B6-hIL2 mice can be used for research into the pathogenesis of autoimmune disorders like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, Sjögren's syndrome, multiple sclerosis, and type 1 diabetes, as well as for the screening, development, and safety evaluation of IL2-targeted drugs.
The IL2 gene encodes Interleukin-2, a crucial cytokine primarily secreted by activated CD4+ and CD8+ T lymphocytes, and to a lesser extent, by natural killer (NK) cells. This protein, also known as T-cell growth factor, plays a pivotal role in regulating immune responses by promoting the growth, proliferation, and differentiation of various "disease-fighting blood cells", including T cells, B cells, NK cells, monocytes, macrophages, and oligodendrocytes [1]. IL2 expression is tightly regulated; it is upregulated upon T-cell activation through T-cell receptor signaling and can be inhibited by factors like TOB and TGF-beta [2]. The encoded IL-2 protein mediates its effects by binding to the IL-2 receptor (IL-2R), a complex found on lymphocytes, which then activates downstream signaling pathways such as JAK-STAT, PI3K/Akt/mTOR, and MAPK/ERK, influencing T-cell survival, differentiation, and the maintenance of immune tolerance by supporting regulatory T cells (Tregs) while inhibiting pro-inflammatory Th17 cell differentiation [3]. Deregulation of IL2 function, whether due to deficiency or excess, is implicated in various autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, Sjögren's syndrome, and multiple sclerosis, as well as certain cancers like metastatic melanoma, renal cell carcinoma, and non-Hodgkin lymphoma [4]. The B6-hIL2 mouse is a humanized model, constructed by replacing the coding sequences of the endogenous mouse Il2 gene with the coding sequences of the human IL2 gene. B6-hIL2 mice can be used for research into the pathogenesis of autoimmune disorders like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, Sjögren's syndrome, multiple sclerosis, and type 1 diabetes, as well as for the screening, development, and safety evaluation of IL2-targeted drugs.
NKG-Rosa26-CAG-hIL2
製品ID :
C001842
系統:
NKG
状況:
Live Mouse
説明:
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, exhibits reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues. In immunology research, direct studies on mice may not fully represent the human immune system due to physiological and immune system differences. However, by transplanting human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) into immunodeficient mice, we can partially or completely replace the mouse immune system with a human counterpart. This approach enables in vivo simulation of human immune system function, providing an effective model for studying human immunity. However, in actual human-mouse xenotransplantation, due to the lack of specific human cytokines and supportive stromal cells in mice, transplantation using conventional immunodeficient mice is likely to result in variations in immune reconstitution efficiency. Modifying immunodeficient mice via gene editing technology to establish a humanized immune microenvironment in mice and promote the functional maturation of human-derived cells is a universal strategy for improving the efficiency of immune reconstitution in xenotransplantation. The IL2 gene encodes Interleukin-2, a crucial cytokine primarily secreted by activated CD4+ and CD8+ T lymphocytes, and to a lesser extent, by natural killer (NK) cells. This protein, also known as T-cell growth factor, plays a pivotal role in regulating immune responses by promoting the growth, proliferation, and differentiation of various "disease-fighting blood cells", including T cells, B cells, NK cells, monocytes, macrophages, and oligodendrocytes [1]. IL2 expression is tightly regulated; it is upregulated upon T-cell activation through T-cell receptor signaling and can be inhibited by factors like TOB and TGF-beta [2]. The encoded IL-2 protein mediates its effects by binding to the IL-2 receptor (IL-2R), a complex found on lymphocytes, which then activates downstream signaling pathways such as JAK-STAT, PI3K/Akt/mTOR, and MAPK/ERK, influencing T-cell survival, differentiation, and the maintenance of immune tolerance by supporting regulatory T cells (Tregs) while inhibiting pro-inflammatory Th17 cell differentiation [3]. Deregulation of IL2 function, whether due to deficiency or excess, is implicated in various autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, Sjögren's syndrome, and multiple sclerosis, as well as certain cancers like metastatic melanoma, renal cell carcinoma, and non-Hodgkin lymphoma [4]. NKG-Rosa26-CAG-hIL2 mouse is a model constructed via gene editing technology, in which the CAG promoter-Human IL2 cDNA-rBG pA cassette is cloned into intron 1 of ROSA26. Compared to NKG mice, NKG-Rosa26-CAG-hIL2 mice support the engraftment and reconstitution of human T cells after transplantation with human cells (such as PBMC or HSC), optimizing the outcome of immune reconstitution. This model provides an excellent experimental platform for human immune system reconstitution, cell or tissue transplantation, and the screening of anti-tumor drugs.
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, exhibits reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues. In immunology research, direct studies on mice may not fully represent the human immune system due to physiological and immune system differences. However, by transplanting human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) into immunodeficient mice, we can partially or completely replace the mouse immune system with a human counterpart. This approach enables in vivo simulation of human immune system function, providing an effective model for studying human immunity. However, in actual human-mouse xenotransplantation, due to the lack of specific human cytokines and supportive stromal cells in mice, transplantation using conventional immunodeficient mice is likely to result in variations in immune reconstitution efficiency. Modifying immunodeficient mice via gene editing technology to establish a humanized immune microenvironment in mice and promote the functional maturation of human-derived cells is a universal strategy for improving the efficiency of immune reconstitution in xenotransplantation. The IL2 gene encodes Interleukin-2, a crucial cytokine primarily secreted by activated CD4+ and CD8+ T lymphocytes, and to a lesser extent, by natural killer (NK) cells. This protein, also known as T-cell growth factor, plays a pivotal role in regulating immune responses by promoting the growth, proliferation, and differentiation of various "disease-fighting blood cells", including T cells, B cells, NK cells, monocytes, macrophages, and oligodendrocytes [1]. IL2 expression is tightly regulated; it is upregulated upon T-cell activation through T-cell receptor signaling and can be inhibited by factors like TOB and TGF-beta [2]. The encoded IL-2 protein mediates its effects by binding to the IL-2 receptor (IL-2R), a complex found on lymphocytes, which then activates downstream signaling pathways such as JAK-STAT, PI3K/Akt/mTOR, and MAPK/ERK, influencing T-cell survival, differentiation, and the maintenance of immune tolerance by supporting regulatory T cells (Tregs) while inhibiting pro-inflammatory Th17 cell differentiation [3]. Deregulation of IL2 function, whether due to deficiency or excess, is implicated in various autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, Sjögren's syndrome, and multiple sclerosis, as well as certain cancers like metastatic melanoma, renal cell carcinoma, and non-Hodgkin lymphoma [4]. NKG-Rosa26-CAG-hIL2 mouse is a model constructed via gene editing technology, in which the CAG promoter-Human IL2 cDNA-rBG pA cassette is cloned into intron 1 of ROSA26. Compared to NKG mice, NKG-Rosa26-CAG-hIL2 mice support the engraftment and reconstitution of human T cells after transplantation with human cells (such as PBMC or HSC), optimizing the outcome of immune reconstitution. This model provides an excellent experimental platform for human immune system reconstitution, cell or tissue transplantation, and the screening of anti-tumor drugs.
Items: 1 to 2 of 2
1
さらに
すべてのフィルター
Strain Type
Mouse
Rat
Modification Type
Knockout
Conditional Knockout
Knockin
Point Mutation
Transgenic
Conditional Knockin
Others
Status
Live Mice
R&D
Frozen Sperm
Validation Data
Verified
In Progress
リセット
確認する
モデルライブラリ
モデルライブラリ
リソース
リソース
動物の品質
動物の品質
サポートを受ける
サポートを受ける
住所:
〒543-0071 大阪府大阪市天王寺区生玉町2-3 小出ビル410室
電話 :
06-7652-3321
メール:
[email protected]
モデル製品
HUGO-Ab™(抗体開発)HUGO-GT™(ヒト化ゲノムオルソログ)MouseAtlas モデルライブラリ研究用動物モデル
サービス
神経科学眼科分野がん研究代謝・循環器系疾患自己免疫・炎症疾患
会社案内
企業概要施設概要動物の健康・福祉健康報告書協力企業・代理店採用情報お問い合わせ
SNS
免責事項:当社の製品およびサービスの価格や入手可能性は地域によって異なります。記載されている価格は特定の国々に適用されます。詳細についてはご連絡ください。
Copyright © 2025 Cyagen. All rights reserved.
プライバシーポリシー
サイトマップ
Cyagenの最新情報をお届けします
研究モデル、CROサービス、科学リソース、特別オファーに関する最新情報を、研究ニーズに合わせてメールでお届けします。
お名前
メール
ご所属機関
関心分野
主な研究分野